The Evolution of the Bone Turnover Marker in Patients Following Recovery from Diabetic Ketoacidosis

Abstract

The aim of the study was to investigate whether the biomarkers for bone turnover could rapidly recover during the period of diabetic ketoacidosis (DKA). Bone turnover biomarkers, including 25-hydroxyvitamin D3, N-terminal middle molecular fragment of osteocalcin (NMID), and β-C terminal cross-linking telopeptide of type 1 collagen were evaluated using in-patient data (n=627) from Shanghai Pudong Hospital from 2018–2022. The comparison was performed between type 2 diabetes (T2D only) (n=602) and DKA (n=25), in which we checked the bone turnover markers at pre-treatment and recovery. After matching by body mass index (BMI), we found that except for 25-OH-VitD3, the age difference, indices of glucose metabolism, and bone turnover were significant between the 2 groups (p<0.05). We found only a significant restoration of NMID (p<0.001). NMID and β-CTX, when compared with T2D, showed overt distinction between recovery and T2D (p<0.05). In addition, the investigations demonstrated a substantial difference between 25-OH-VitD3 in males and NMID in females, regardless of age (p<0.05). Multilinear regression analysis revealed that 2 hours postprandial plasma C-peptide was an independent predictor of the NMID in both pre-treatment (β=0.58, p=0.003) and recovery (β=0.447, p=0.025), although sex was significant in pre-treatment (β=–0.444, p=0.020). Finally, we found that only age variation affected DKA’s fasting plasma glucose level (p<0.05). The study revealed that the bone turnover of DKA is significantly different in pre-treatment and recovery; however, NMID might recover quickly if the patients received appropriate treatment. Importantly, pancreatic function plays a critical role in changing bone turnover biomarkers.

Keywords

diabetic ketoacidosis - bone turnover markers - pancreatic function

Publication History

Received: 17 October 2023

Accepted after revision: 09 January 2024

Article published online:
12 February 2024

• References

• 1 Federation ID. IDF diabetes atlas. 10th edn Brussels, Belgium: International Diabetes Federation; 2021
• 2 Anon. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care 2022; 45: S17-S38
• 3 Zhang M, Li Y, Cui W. et al. The clinical and metabolic characteristics of young-onset ketosis-prone type 2 diabetes in China. Endocr Pract 2015; 21: 1364-1371
• 4 Ye S, Ran H, Zhang H. et al. Elevated serum triglycerides are associated with ketosis-prone type 2 diabetes in young individuals. Diabetes Metab Syndr Obes 2021; 14: 497-504
• 5 Schacter GI, Leslie WD. Diabetes and bone disease. Endocrinol Metab Clin North Am 2017; 46: 63-85
• 6 Xu C, Gong M, Wen S. et al. The comparative study on the status of bone metabolism and thyroid function in diabetic patients with or without ketosis or ketoacidosis. Diabetes Metab Syndr Obes 2022; 15: 779-797
• 7 Chen Y, Zhang W, Chen C. et al. Thyroid and bone turnover markers in type 2 diabetes: results from the METAL study. Endocr Connect 2022; 11: e210484
• 8 Pirro M, Manfredelli MR, Scarponi AM. et al. Association between thyroid hormone levels, the number of circulating osteoprogenitor cells, and bone mineral density in euthyroid postmenopausal women. Metabolism 2012; 61: 569-576
• 9 Liu C, Pan J, Wen S. et al. Low TSH levels within euthyroid range could play a negative role on bone mineral density in postmenopausal women with type 2 diabetes. Diabetes Metab Syndr Obes 2021; 14: 2349-2355
• 10 Iwamoto Y, Kimura T, Tatsumi F. et al. Effect of hyperglycemia-related acute metabolic disturbance on thyroid function parameters in adults. Front Endocrinol (Lausanne) 2022; 13: 869869
• 11 Eledrisi MS, Alkabbani H, Aboawon M. et al. Clinical characteristics and outcomes of care in patients hospitalized with diabetic ketoacidosis. Diabetes Res Clin Pract 2022; 192: 110041
• 12 Preechasuk L, Tantasuwan S, Likitmaskul S. et al. Clinical characteristics, glycemic control, and microvascular complications compared between young-onset type 1 and type 2 diabetes patients at Siriraj hospital - a tertiary referral center. Diabetes Metab Syndr Obes 2022; 15: 1375-1387
• 13 Masuda S, Ota K, Okazaki R. et al. Clinical characteristics associated with the development of diabetic ketoacidosis in patients with type 2 diabetes. Intern Med 2022; 61: 1125-1132
• 14 Chai J, Sun Z, Zhou Q. et al. Evaluation of trace elements levels and construction of auxiliary prediction model in patients with diabetes ketoacidosis in type 1 diabetes. Diabetes Metab Syndr Obes 2023; 16: 3403-3415
• 15 Shao P, Guo S, Li G. et al. Determinants of deranged thyroid function parameters in children admitted for management of diabetic ketoacidosis/diabetic ketosis. BMC Endocr Disord 2020; 20: 135
• 16 Zoch ML, Clemens TL, Riddle RC. New insights into the biology of osteocalcin. Bone 2016; 82: 42-49
• 17 Mizokami A, Yasutake Y, Gao J. et al. Osteocalcin induces release of glucagon-like peptide-1 and thereby stimulates insulin secretion in mice. PLoS One 2013; 8: e57375
• 18 Mizokami A, Yasutake Y, Higashi S. et al. Oral administration of osteocalcin improves glucose utilization by stimulating glucagon-like peptide-1 secretion. Bone 2014; 69: 68-79
• 19 Riddle RC, Frey JL, Tomlinson RE. et al. Tsc2 is a molecular checkpoint controlling osteoblast development and glucose homeostasis. Mol Cell Biol 2014; 34: 1850-1862
• 20 Evans AL, Paggiosi MA, Eastell R. et al. Bone density, microstructure and strength in obese and normal weight men and women in younger and older adulthood. J Bone Mineral Res 2015; 30: 920-928
• 21 Ma M, Liu X, Jia G. et al. The association between body fat distribution and bone mineral density: evidence from the US population. BMC Endocr Disord 2022; 22: 170
• 22 Huynh T, Greer RM, Nyunt O. et al. The association between ketoacidosis and 25(OH)-vitamin D levels at presentation in children with type 1 diabetes mellitus. Pediatr Diabetes 2009; 10: 38-43